TAILIEUCHUNG - Evaluation of the operation outcomes of non small cell lung cancer stage I - IIIA in Hanoi Medical University Hospital

Objectives: To evaluate the operation outcomes of stage I - IIIA non-small cell lung cancer patients in Hanoi Medical University Hospital. Subjects and methods: The retrospective descriptive study of 30 non-small cell lung cancer patients staged I to IIIA. | Journal of military pharmaco-medicine no1-2019 EVALUATION OF THE OPERATION OUTCOMES OF NON-SMALL CELL LUNG CANCER STAGE I - IIIA IN HANOI MEDICAL UNIVERSITY HOSPITAL Le Van Quang1; Trinh Le Huy1; Mai Thi Kim Ngan1 Nguyen Van Dang1; Nguyen Xuan Hau1 SUMMARY Objectives: To evaluate the operation outcomes of stage I - IIIA non-small cell lung cancer patients in Hanoi Medical University Hospital. Subjects and methods: The retrospective descriptive study of 30 non-small cell lung cancer patients staged I to IIIA. Results: Lobectomy was , lung excision was only . The average of operating time was ± hours. The blood loss during operation was 200 ± 25 mL. Postoperative complications: ( surgical bleeding, subcutaneous emphysema). The average hospitalization length was 8 ± days. The duration of postoperative analgesia was 7 ± days. The disease free survival rates at 12, 24, 36 months: 86%, 76%, 66%. The overall survival at 12, 24, 36 months: 100%, 93%, . Conclusion: Surgery for non-small cell lung cancer stage I - IIIA in the Oncology and Palliative Care Department, Hanoi Medical University Hospital had a good surgical and oncological results. * Keywords: Non-small cell lung cancer; Stage I - IIIA; Surgical outcome. INTRODUCTION Lung cancer is the most common cancer in men and is the leading cause of death in cancer patient. Lung cancer has a poor prognosis because of rapid progression, early metastasis and late diagnosis. Therefore, the indication of surgery is very limited. However, in recent years, the rapid development of diagnostic techniques has helped to detect the disease at earlier stages, so that the patients can be good candidates for surgery. Surgery for lung cancer at the Department of Oncology and Palliative Care of Hanoi Medical University Hospital has been done since 2009. The primiliary results are promising. However, these results must be accurately and scientifically assessed by a strict study. Therefore, we .

• Y khoa - Dược
• Non small cell lung cancer
• Stage I IIIA
• Surgical outcome
• Pulmonary disease
• Patients with lung cancer
• C T1N0M0 primary lung cancer
• Journal of Biology
• Epidermal growth factor receptor
• Nonsmall cell lung cancer
• Lung cancer
• Phosphoinositide kinase
• Quantitative reverse transcription polymerase chain reaction (qRT PCR)
• BMC Pulmonary Medicine
• Small cell lung cancer
• Traditional histopathology
• Certain limitations
• BMC Cancer
• Brain metastasis
• Tyrosine kinase inhibitors
• Tumor mutation burden
• Meta analysis
• SET domain containing 5
• ERK signaling
• Lymph node metastasis
• Oncogenic lncRNA
• Lung adenocarcinoma
• Therapeutic approaches
• Tumor protein 53
• Anaplastic lymphoma kinase
• Risk factors
• Post recurrence survival
• Overall recurrence
• Performance status
• Best supportive care
• Overall survival
• Immune checkpoint inhibitor
• Immune related adverse events
• Re challenge
• Fluorescence in situ hybridization
• Massive parallel sequencing
• Circulating biomarker
• Thrombospondin 1
• Tumor microenvironment
• Feasibility study
• Cytotoxic agents prolongs survival
• Cytotoxic agent plus bevacizumab
• Epidermal growth factor receptor mutation
• Tyrosine kinase inhibitor
• Stereotactic ablative radiation therapy
• Oligometastatic tumor
• Lung metastasis
• Colorectal carcinoma
• Dose response relationship
• EGFR mutation
• Targeted therapy
• Personalized medicine
• Radiologic biomarkers
• Angiogenesis inhibitors
• Tumor angiogenesis
• Uncommon mutations
• Brain metastases
• Real world
• Camphor cytotoxicity
• DNA damaging
• DNA protective
• Drug resistant human lung cancer cell lines
• Non small cell lung carcinoma
• EGFR mutated patients
• Personalized medicine for effective treatment
• Targeted therapeutic drugs is reviewed
• Mutation specific immunohistochemistry
• Modelling and simulation
• Computational oncology
• Malignant pleural mesothelioma
• Toxicity balance
• Low dose radiation
• T cells
• Intensity modulated radiation technique
• Genome Biology
• Splicing isoform
• Long read sequencing
• Aberrant splicing isoform
• Cancer cells